DexCom Inc (DXCM) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.

Total Revenue Chart for DexCom Inc

DexCom Inc (DXCM) revenue for FY2025 was USD 4.7B, a 15.6% change from FY2024. DexCom Inc's revenue grew from USD 2.2M in 2006 to USD 4.7B in 2025 (214759.5% over 19 years). Earnings per share moved from USD -0.17 in 2011 to USD 0.80 in 2022. Revenue compound annual growth rate: 5-year CAGR of 19.3%, 10-year CAGR of 27.8%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$31.19B
Implied Share Price
$82.66
Enterprise Value
$32.26B
Revenue (TTM)
$4.97B
EBITDA
$1.40B
Profit Margin
20.12%
Trailing P/E
32.67
Forward P/E
34.36
Price/Book (MRQ)
12.52
Price/Sales (TTM)
6.30
EV/EBITDA
20.69
EV/Revenue
6.49
Dividend Yield
—
Book Value
$6.95
Free Cash Flow (FY2025)
$1.08B
Free Cash Flow Yield
3.45%

Snapshot as of 5th August 2026 — not point-in-time controlled, may lag the live market by a few days.